Nasal Polyposis - Epidemiology Forecast - 2032

This ‘Nasal Polyposis - Epidemiology Forecast-2032' report delivers an in-depth understanding of Nasal Polyposis, historical and forecasted epidemiology as well as Nasal Polyposis trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Nasal Polyposis Disease Understanding

Nasal Polyposis/Nasal polyps are small, benign drop-like growths appearing in the mucosa (lining tissues) of the nose and may block the nasal passageway. Nasal Polyposis tends to be present on both sides of the nasal cavity. Small Nasal Polyposis may not reflect any symptoms, but the larger growths or groups of Nasal Polyposis can block the nasal passages or lead to breathing problems, a lost sense of smell, and frequent infections. One-sided Nasal Polyposis may need to be investigated further as they might be malignant nasal or sinus tumors.

Nasal Polyposis are a subgroup of chronic rhinosinusitis. Chronic rhinosinusitis is a condition where the nasal cavity and sinuses are inflamed for more than 4 to 12 weeks. Patients suffering from chronic rhinosinusitis condition can be progressed into chronic rhinosinusitis with NP (CRSwNP), and chronic rhinosinusitis without NP (CRSsNP). Only a portion of chronic rhinosinusitis will develop Nasal Polyposis. CRSwNP is a potentially debilitating condition in adults that are characterized by inflammation of the nose and paranasal sinuses with the presence of Nasal Polyposis.

People with a history of chronic sinus infections, allergic rhinitis, asthma, cystic fibrosis, sensitivity to NSAIDs like ibuprofen and aspirin, and Churg-Strauss syndrome are more prone to getting Nasal Polyposis. Patients suffering from NP may experience chronic nasal congestion, running nose, postnasal drip, reduced sense of smell and taste, difficulty in breathing, pressure in the face or forehead area, snoring, sleep apnea, and others.

Nasal Polyposis Diagnosis

The diagnosis of Nasal Polyps is based on a combination of history, physical examination, and often a sinus CT scan. The history of nasal congestion and loss of smell points to Nasal Polyps. Nasal examination often by nasal endoscopy confirms the diagnosis of nasal polyps and distinguishes patients with CRSwNP from patients with CRSwNP. A sinus CT scan is helpful because it documents the extent of sinus disease.

Nasal Polyposis Epidemiology Perspective

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by prevalent cases of chronic rhinosinusitis, diagnosed prevalent cases of chronic rhinosinusitis, diagnosed prevalent cases of Nasal Polyposis, and gender-specific diagnosed prevalent cases of Nasal Polyposis, the scenario of Nasal Polyposis in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2019 to 2032.

Nasal Polyposis Detailed Epidemiology Segmentation

• The total prevalent cases of chronic rhinosinusitis in the 7MM were found to be 69,550,461 cases in 2021. The prevalent cases of chronic rhinosinusitis are expected to rise by 2032.
• Among all the 7MM countries, the United States accounted for the highest diagnosed prevalent cases (8,691,874 cases) of chronic rhinosinusitis in 2021.
• In 2021, the total reported diagnosed prevalent cases of Nasal Polyposis in the 7MM countries were 4,358,603 cases which are expected to increase by 2032.
• In 2021, Germany accounted for the highest number of Nasal Polyposis diagnosed prevalent cases (617,716 cases), followed by the United Kingdom (435,157 cases) among EU-5 countries. In contrast, Spain accounted for the lowest number of Nasal Polyposis diagnosed prevalent cases in EU-5.
• As per the analysis, in Japan, most of the diagnosed prevalent cases of Nasal Polyposis were reported in males. In 2021, there were 111,545 diagnosed prevalent cases of Nasal Polyposis among males and 91,264 cases among females in Japan.

Scope of the Report

• The report covers a descriptive overview of Nasal Polyposis, explaining its symptoms, grading, pathophysiology, and various diagnostic approaches.
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
• The report assesses the disease risk and burden of Nasal Polyposis.
• The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
• The report provides the segmentation of the disease epidemiology for 7MM, a total number of prevalent cases of chronic rhinosinusitis, diagnosed prevalent cases of chronic rhinosinusitis, diagnosed prevalent cases of Nasal Polyposis, and gender-specific diagnosed prevalent cases of Nasal Polyposis.

Report Highlights

• 11-Year Forecast of Nasal Polyposis
• The 7MM Coverage
• Prevalent cases of chronic rhinosinusitis
• Diagnosed prevalent cases of chronic rhinosinusitis
• Diagnosed prevalent cases of Nasal Polyposis
• Gender-specific diagnosed prevalent cases of Nasal Polyposis

Key Questions Answered

• What are the disease risk and burdens of Nasal Polyposis?
• What is the historical Nasal Polyposis patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
• What would be the forecasted patient pool of Nasal Polyposis at the 7MM level?
• What will be the growth opportunities across the 7MM concerning the patient population for Nasal Polyposis?
• Out of the above-mentioned countries, which country would have the highest diagnosed prevalent population of Nasal Polyposis during the forecast period (2022-2032)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2022-2032)?

Reasons to Buy

The Nasal Polyposis report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the 7MM Nasal Polyposis epidemiology forecast.
• The Nasal Polyposis epidemiology report and model were written and developed by Master's and Ph.D. level epidemiologists.
• The Nasal Polyposis epidemiology model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports the data presented in the report and showcases disease trends over the 11-year forecast period using reputable sources.

Key Assessments

• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019-2032